Literature DB >> 31095103

Human Immunodeficiency Virus Incidence Among Women at High-Risk of Human Immunodeficiency Virus Infection Attending a Dedicated Clinic in Kampala, Uganda: 2008-2017.

Ivan Kasamba, Stephen Nash, Janet Seeley, Helen A Weiss.   

Abstract

BACKGROUND: High attrition and irregular testing for human immunodeficiency virus (HIV) in cohort studies for high-risk populations can bias incidence estimates. We compare incidence trends for high-risk women attending a dedicated HIV prevention and treatment clinic, using common methods for assigning when seroconversion occurs and whether seroconversion occurs among those with attrition.
METHODS: Between April 2008 and May 2009, women were enrolled into cohort 1 and from January 2013 into cohort 2, then scheduled for follow-up once every 3 months. Incidence trends based on assuming a midpoint in the seroconversion interval were compared with those of assigning a random-point. We also compared estimates based on the random-point with and without multiple imputation (MI) of serostatuses for participants with attrition.
RESULTS: By May 2017, 3084 HIV-negative women had been enrolled with 18,364 clinic visits. Before attrition, 27.6% (6990 of 25,354) were missed visits. By August 2017, 65.8% (426 of 647) of those enrolled in cohort 1 and 49.0% (1194 of 2437) in cohort 2 were defined with attrition. Among women with 1 or more follow-up visit, 93 of 605 in cohort 1 and 77 of 1601 in cohort 2 seroconverted. Periods with longer seroconversion intervals appeared to have noticeable differences in incidences when comparing the midpoint and random-point values. The MI for attrition is likely to have overestimated incidence after escalated attrition of participants. Based on random-point without MI for attrition, incidence at end of observation was 3.8/100 person-years in cohort 1 and 1.8/100 in cohort 2.
CONCLUSIONS: The random-point approach attenuated variation in incidence observed using midpoint. The high incidence after years of ongoing prevention efforts in this vulnerable population should be investigated to further reduce incidence.

Entities:  

Mesh:

Year:  2019        PMID: 31095103     DOI: 10.1097/OLQ.0000000000000978

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  5 in total

1.  Comparison of retention in observational cohorts and nested simulated HIV vaccine efficacy trials in the key populations in Uganda.

Authors:  Andrew Abaasa; Jim Todd; Stephen Nash; Yunia Mayanja; Pontiano Kaleebu; Patricia E Fast; Matt Price
Journal:  BMC Med Res Methodol       Date:  2020-02-12       Impact factor: 4.615

2.  The Molecular Epidemiology and Transmission Dynamics of HIV Type 1 in a General Population Cohort in Uganda.

Authors:  Deogratius Ssemwanga; Nicholas Bbosa; Rebecca N Nsubuga; Alfred Ssekagiri; Anne Kapaata; Maria Nannyonjo; Faridah Nassolo; Alex Karabarinde; Joseph Mugisha; Janet Seeley; Gonzalo Yebra; Andrew Leigh Brown; Pontiano Kaleebu
Journal:  Viruses       Date:  2020-11-10       Impact factor: 5.048

3.  Use of propensity score matching to create counterfactual group to assess potential HIV prevention interventions.

Authors:  Andrew Abaasa; Yunia Mayanja; Gershim Asiki; Matt A Price; Patricia E Fast; Eugene Ruzagira; Pontiano Kaleebu; Jim Todd
Journal:  Sci Rep       Date:  2021-03-29       Impact factor: 4.379

4.  Phylogenetic Networks and Parameters Inferred from HIV Nucleotide Sequences of High-Risk and General Population Groups in Uganda: Implications for Epidemic Control.

Authors:  Nicholas Bbosa; Deogratius Ssemwanga; Rebecca N Nsubuga; Noah Kiwanuka; Bernard S Bagaya; John M Kitayimbwa; Alfred Ssekagiri; Gonzalo Yebra; Pontiano Kaleebu; Andrew Leigh-Brown
Journal:  Viruses       Date:  2021-05-24       Impact factor: 5.048

5.  Phylogenetic and Demographic Characterization of Directed HIV-1 Transmission Using Deep Sequences from High-Risk and General Population Cohorts/Groups in Uganda.

Authors:  Nicholas Bbosa; Deogratius Ssemwanga; Alfred Ssekagiri; Xiaoyue Xi; Yunia Mayanja; Ubaldo Bahemuka; Janet Seeley; Deenan Pillay; Lucie Abeler-Dörner; Tanya Golubchik; Christophe Fraser; Pontiano Kaleebu; Oliver Ratmann
Journal:  Viruses       Date:  2020-03-18       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.